Osimertinib In EGFR Mutant Lung Cancer
Clinical trial NCT03586453 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03586453
- Sponsor
- Dana-Farber Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-08-13
- Primary completion
- 2028-02-28
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.